Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

Schizophrenia - aripiprazole: review decison - July 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 76 KB)

Review Proposal - May 2011 information

Appendix A: provisional matrix of stakeholders (PDF 60 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 123 KB)

TA213 Schizophrenia - aripiprazole: press release information

Download PDF version information

2011 011 Schizophrenia - aripiprazole (PDF 72 KB)

Schizophrenia - aripiprazole: equality impact assessment (PDF 22 KB)

Schizophrenia - aripiprazole: final appraisal determination information

Schizophrenia - aripiprazole: final appraisal determination guidance (PDF 219 KB)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 149 KB)

Consultee and commentator comments on the Appraisal Consultation Document

Bristol Myers Squibb (also on behalf of Otsuka Pharmaceuticals): covering letter (PDF 60 KB)

Bristol Myers Squibb (also on behalf of Otsuka Pharmaceuticals): response (PDF 338 KB)

Royal College of Paediatrics and Child Health (PDF 19 KB)

Comments on the Appraisal Consultation Document received through the NICE website (PDF 21 KB)

Aripiprazole for the treatment of schizophrenia in people aged 15-17: appraisal consultation

Schizophrenia - aripiprazole: appraisal consultation document information

Schizophrenia - aripiprazole: evaluation report

Schizophrenia - aripiprazole: pre-meeting brief (PDF 203 KB)

Schizophrenia - aripiprazole: Evidence Review Group report (PDF 770 KB)

Schizophrenia - aripiprazole: Evidence Review Group report addendum (PDF 131 KB)

Schizophrenia - aripiprazole: manufacturer submission (PDF 1.87 MB)

Schizophrenia - aripiprazole: NICE clarification letter (PDF 29 KB)

Schizophrenia - aripiprazole: manufacturer response to clarification letter (PDF 243 KB)

Schizophrenia - aripiprazole: non-manufacturer submissions

Schizophrenia - aripiprazole: manufacturer submission - Royal College of Nursing (PDF 30 KB)

Schizophrenia - aripiprazole: manufacturer submission - Royal College of Paediatrics and Child Health (PDF 27 KB)

Schizophrenia - aripiprazole: expert written personal statements

Schizophrenia - aripiprazole: expert written personal statements - Lamb (PDF 150 KB)

Schizophrenia - aripiprazole: expert written personal statements - McDougall (PDF 20 KB)

Schizophrenia - aripiprazole: expert written personal statements - Antoniou (PDF 38 KB)

Schizophrenia - aripiprazole: expert written personal statements - Travis (PDF 47 KB)

Schizophrenia - aripiprazole: provisional matrix (PDF 30 KB)

Schizophrenia - aripiprazole: draft scope (PDF 32 KB)